CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 31 enrolled
Drug / intervention
Atazanavirdrug
Likely dose
Atazanavir 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01388543
NCT01388543Phase 4Completed
CompareCT.gov

Genetic-determinants of Protease Inhibitor Pharmacology

University of Colorado, Denver·interventional·Posted Jul 6, 2011·Updated Nov 19, 2019

In Brief

A Phase 4 clinical trial evaluating Atazanavir for HIV. Completed, enrolled 31 participants across 1 site.

Detailed Summary

This study evaluated the blood levels of atazanavir according to a genetic makeup for CYP3A5 (cytochrome P450 3A5, an enzyme that metabolizes atazanavir). The hypothesis was that people with a slow-metabolizing genotype would have higher blood levels of atazanavir compared to people with the normal metabolizing genotype.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV
CountriesUnited States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 6, 2011
Enrollment StartSep 1, 2006
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 15.0 years ago

Interventions

Atazanavirdrug

Atazanavir 400mg once daily for 7 days followed by atazanavir 300mg plus ritonavir 100mg for 7 days